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Background: Monitoring trends in mortality for indi-
viduals diagnosed with hepatitis C virus (HCV) infec-
tion are important as we expand treatment and move 
towards World Health Organization elimination tar-
gets. Aim: To estimate mortality rates for individu-
als aged ≥ 15 years diagnosed with HCV infection in 
England 2008–16. Methods: An observational cohort 
study whereby death certificate information was 
linked to the Sentinel Surveillance of Blood Borne 
Virus Testing in England. Age-sex standardised mor-
tality rates (ASMR) for individuals diagnosed with HCV 
infection (2008–16) were calculated and compared to 
the general population. Results: Of 43,895 individu-
als with HCV infection, 2,656 (6.3%) died. All-cause 
ASMRs were 2,834.2 per 100,000 person years (PY), 
2.3 times higher than in the general population. In 
individuals aged 30–69 years, all-cause mortality 
rates were 1,768.9 per 100,000 PY among individu-
als with HCV, 4.7 times higher than in the general 
population. ASMRs had not decreased between 2010 
(2,992) and 2016 (2,340; p=0.10), with no change 
from 2014 (p = 0.058). ASMRs were 441.0 times higher 
for hepatitis, 34.4 times higher for liver cancer, 8.1 
times higher for end stage liver disease and 6.4 times 
higher for external causes than in the general popula-
tion. Conclusions: Mortality was higher in individuals 
with diagnosed HCV infection compared to the general 
population, highlighting health inequalities. There is 
a need to improve HCV diagnosis, engagement in care 
and treatment rates. The high mortality from external 
causes highlights the importance of integrated health 
and social care strategies and addressing the needs of 
this vulnerable population.
Introduction
In England, an estimated 0.4% (160,000) of the popu-
lation have chronic hepatitis C virus (HCV) infection, 
with the main group at risk of HCV infection being 
persons who inject drugs (PWID) [1]. Individuals with 
chronic HCV infection are at increased risk of liver cir-
rhosis, end-stage liver disease (ESLD) and hepatocel-
lular carcinoma (HCC), the burden of which have been 
increasing over the past 10 years [2].
Historically, HCV treatment rates in England have been 
low, however, the treatment landscape for individuals 
with chronic HCV infection has dramatically changed 
following the introduction of direct-acting antivirals 
(DAAs) in 2014, which have a shorter treatment dura-
tion, are better tolerated and are more effective than 
previous interferon-based regimens [3]. Successful 
curative treatment, defined as a sustained virologi-
cal response, improves the outcomes in individuals 
with HCV infection including reduced mortality rates 
[4-6]. With these changes to treatment it is impor-
tant to understand the burden of disease and asso-
ciated mortality in the pre-DAA era. This will enable 
us to effectively monitor their impact on the cascade 
of care (including mortality) taking into account the 
increased efforts to diagnose, engage in care and treat 
individuals with HCV infection. This is particularly rel-
evant as countries across Europe, including the United 
Kingdom (UK), are working towards the World Health 
Organization (WHO) global strategy for elimination of 
viral hepatitis as a significant public health threat by 
2030 and reduction in HCV-associated deaths is one of 
the metrics for monitoring progress [7].
Using information on testing from the Sentinel 
Surveillance of Blood Borne Virus Testing (SSBBV) and 
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Office for National Statistics (ONS) Death Registry in 
England, we aim to estimate mortality rates for individ-
uals (≥ 15 years) first reported to SSBBV with diagnosed 
HCV infection between 2008 and 2016 and describe 
the characteristics of changes that have occurred fol-
lowing the introduction of DAAs in 2014.
Methods
Study design
This is an observational cohort study looking at HCV-
related mortality rates in individuals aged 15 years or 
older, diagnosed with HCV infection between 2008 and 
2016 in England.
Data sources
Sentinel Surveillance of Blood Borne Virus Testing 
(SSBBV)
The sentinel Surveillance of Blood Borne Virus Testing 
(SSBBV), held at Public Health England (PHE), col-
lects hepatitis A-E, HIV and Human T-lymphotropic 
virus (HTLV) testing information from 23 participating 
laboratories in England. Information on tests is col-
lected regardless of result and includes demographics 
(age, sex and ethnicity) and the service requesting the 
test [8,9]. Multiple tests relating to the same person 
are linked using a combination of soundex (phonetic 
algorithm for indexing names), date of birth, National 
Health Service (NHS) number and hospital number. 
Participating laboratories are broadly representative of 
England as a whole and cover ca 40% of the registered 
general practitioner (GP) population in England. When 
possible, the date of first HCV infection diagnosis in 
SSBBV is updated by the routine laboratory reports of 
HCV and Hospital Episode Statistics (HES). Diagnosis 
dates prior to those reported in SSBBV are identified 
in HES where an earlier inpatient stay is recorded with 
viral hepatitis ICD-10 diagnosis codes (B17.1 and B18.2). 
The routine laboratory reports of HCV and HES were 
linked to SSBBV using NHS number, sex and date of 
birth. Following linkage and date of diagnosis improve-
ment, individuals with a diagnosis date for HCV infec-
tion before 2008 were excluded.
Office for National Statistics (ONS) cause of death 
registry
The registry of deaths at ONS, includes all reported 
deaths in England since 1937 [10]. Cause of death 
is coded according to the tenth revision of the 
International Statistical Classification of Diseases and 
Related Health Problems (ICD10 [11]) as underlying 
cause or as one of nine contributory causes.
Data collection and linkage
In 2018, all individuals aged 15 years or older diag-
nosed with HCV infection and first reported to SSBBV 
between 2008 and 2016 were extracted from SSBBV. 
Individuals were excluded if they did not have date of 
birth or sex recorded. NHS laboratories in England sub-
mit positive HCV test results (predominantly anti-HCV, 
some HCV RNA) to the routine laboratory reporting of 
HCV at PHE. The system does not distinguish between 
anti-HCV and HCV RNA positivity and so laboratory 
‘confirmed’ cases are a mix of current and ever infected 
individuals. Data have been collected since 1990, and 
since 2010, HCV infection has been a notifiable causa-
tive agent and all diagnostic laboratories are legally 
required to report new diagnoses to PHE. Data comple-
tion varies over time.
In April 2018, ONS provided all reported deaths 
between 2008 and 2016 in individuals aged 15 years 
or older living in England. Underlying cause of death 
ICD10 codes were grouped according to  Table 1. In 
addition to the groupings we looked at: (i) all-liver dis-
ease mortality (underlying), by grouping liver cancer, 
ESLD, viral hepatitis, alcoholic and non-alcoholic liver 
disease diagnostic codes, and (ii) all-liver disease mor-
tality (underlying and contributory), where liver cancer, 
ESLD, hepatitis, alcoholic and non-alcoholic liver dis-
ease were recorded as either the underlying or contrib-
utory (i.e. as any of the additional nine causes) cause 
of death.
SSBBV and the registry of deaths were linked using a 
deterministic approach i.e. the data were first linked 
using NHS number in conjunction with date of birth 
(then dropping either the day, month or year), the data 
were then linked with soundex (a phonetic algorithm for 
indexing names) and initial before finally being linked 
with soundex and year of birth. In instances where the 
NHS number was not available, we matched on soun-
dex, initial and date of birth. A hierarchical approach 
was used for each year where matches by NHS num-
ber superseded a match without an NHS number. 
Additional checks were conducted on records where a 
person had been tested after their date of death, where 
a person has been linked to a death recorded in a pre-
vious year and where multiple records matched.
Statistical analysis
Overall and disease-specific mortality rates per 
100,000 person years (PY), standardised to the 2013 
European standard population by age and sex, were 
calculated for all individuals (≥ 15 years) and within a 
subset of individuals aged 30–69 years (premature 
mortality). ASMRs for males and females are age-stand-
ardised only. Confidence intervals (CI) were calculated 
using the Poisson distribution [12]. Individual follow-
up began 6 months after HCV diagnosis and ended at 
death (between 2008 and 2016) or 31 December 2016.
Individuals who died within 6 months of their HCV diag-
nosis were excluded from the analysis, as there was 
potential bias towards higher rates of diagnosis in indi-
viduals with major morbidity. Annual age-sex adjusted 
mortality rates (ASMRs) were calculated for the period 
2008 to 2016, allowing trends to be explored for all-
cause, underlying and contributory all-liver disease 
mortality. The small number of people with HCV (who 
died) in 2008 and 2009 (due to very short follow-up 
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times from diagnosis) led to unstable rates for the 
first 2 years of analysis and therefore ASMRs for these 
years were excluded when presenting trends. Joinpoint 
Regression Programme Version 4.2.1.0 (National 
Cancer Institute, Bethesda, United States) was used to 
analyse for changes in ASMRs at 2014, the year when 
DAAs were introduced in England. Joinpoint can iden-
tify statistically significant changes in trend data over 
time and whether there was a point at which a statisti-
cally significant change in the trend occurred [13].
For comparison, ASMRs for the general population 
were estimated using all death reports reported to ONS 
for 2012 divided by the mid-2012 population estimates, 
the mid-point of our analysis period. Mortality rate 
ratios were calculated by dividing the ASMR among 
individuals diagnosed with HCV infection between 
2008 and 2016 by the ASMR among the English popu-
lation in 2012 and 95% CI were calculated by dividing 
the ASMR 95% CI for individuals diagnosed with HCV 
by the ASMR for England.
Ethics
The data were collected for the surveillance of HCV 
infection, including linkage to death registrations 
held by the Office for National Statistics and is cov-
ered by Health Service (Control of Patient Information) 
Regulations 2002 (regulation 3).
Results
During the study period (2008–16), of 43,895 indi-
viduals (≥ 15 years) diagnosed with an HCV infection 
reported to SSBBV, 2,656 (6.3%) had died. Total follow-
up time was 183,821 PY and median follow-up time was 
4.1 years (interquartile range (IQR): 2.1–6.3 years). The 
majority of individuals with HCV infection were male 
(67.6%) and the median age at diagnosis was 39 years 
(IQR: 32–48 years) (Table 2). Of 2,656 individuals who 
died within the follow-up period, the median time from 
diagnosis to death was 3 years (IQR: 1.6–4.7 years).
All-cause ASMR per 100,000 among individuals with 
HCV infection were 2,834.2 per 100,000 PY (Table 3), 
2.3 times higher than that for the general population 
(1,218.5 per 100,000 PY), and were higher in males 
than females (3,170.7 vs 2,497.7 per 100,000 PY). A 
non-significant decrease in ASMRs was observed from 
2,523.4 per 100,000 PY (95% CI: 1,801.6–3,245.2) in 
2010 to 2,438.2 per 100,000 PY (95% CI: 2,106.8–
2,769.6) in 2016 (p = 0.30) (Figure). When examining 
the possibility of a change in trend in 2014, the year 
DAAs became available on the NHS, there was no sig-
nificant difference between the two slopes of best fit 
(p = 0.34).
ASMRs for individuals with a HCV infection diagnosis 
were higher than those in the general population for all 
grouped underlying causes of death. Of note, mortal-
ity rate ratios indicate that compared with the general 
population, individuals with HCV infection were 421.9 
times more likely to die from viral hepatitis, 34.5 times 
more likely from liver cancer, 8.0 times more likely 
from ESLD, 16.5 times more likely from alcoholic liver 
disease, 11.8 times more likely from non-alcoholic liver 
disease and 6.2 times more likely to die from external 
causes than the general population. When deaths from 
liver disease were grouped, ASMRs for underlying all-
liver disease and underlying and contributory all-liver 
disease were 28.4 and 40.2 times higher, respectively, 
than for the general population. A non-significant 
decrease in ASMRs for underlying and contributory all-
liver disease was observed, from 975.0 (95% CI: 619.1–
1,331.0) in 2010 to 875.4 (95% CI: 395.9–1,054.9) in 
2016 (p = 0.3).
Premature mortality
In individuals aged 30–69 years, all-cause ASMR was 
1,768.9 per 100,000 PY among individuals with a HCV 
infection diagnosis, 4.7 times higher than the general 
population (England ASMR: 377.9 per 100,000 PY) 
(Table 3).
ASMRs per 100,000 PY in individuals aged 30–69 years 
were higher in men than women (2,016.5 vs 1,431.3 
per 100,000 PY) and when compared with the general 
population. In this age group, ASMRs for all grouped 
causes of death were 263.6 times higher for viral hep-
atitis, 39.5 times higher for liver cancer, 16.8 times 
higher for alcoholic liver disease, 14.8 times higher 
for non-alcoholic liver disease, 8.9 times higher for 
ESLD and 11.2 times higher for external causes. ASMRs 
from underlying all-liver disease and underlying and 
Table 1
Primary cause of death groupings, with ICD10 codes
Cause of death grouping IDC10 Codes
Viral hepatitis B15–19
End stage liver disease I850, I983, K704, K720, K721, K729, K767, R18
Liver cancer C22
Alcoholic liver disease K70, excluding K704
Non-alcoholic liver disease K71-K77, excluding K720, K721, K729, K767
External causes S00–99, T00–98, V01–99, W00-W99, X00-X99, Y00-Y98
Other All other ICD-10 codes
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contributory all-liver disease were 655.5 and 917.8 per 
100,000 PY, respectively; 25.8 and 25.2 times higher 
per 100,000 PY than in the general population.
Discussion
ASMRs for individuals diagnosed with HCV in England 
between 2008 and 2016 were more than two times 
higher than that found in the general population with 
higher rates in men than women. Mortality rates were 
between 8.0 and 421.9 times higher in individuals with 
HCV infection diagnosis for liver causes (ESLD, liver 
cancer, viral hepatitis, alcoholic and non-alcoholic 
liver disease) than for the general population and rates 
were 28.4 and 40.2 times higher, respectively, when 
underlying and contributory causes of death were 
included. Mortality rates for external causes were 6.2 
times higher than in the general population and more 
pronounced in individuals aged 30–69 years. This may 
indicate a higher risk of premature mortality not only 
from liver related causes but also from overdose, inten-
tional self-harm and accidents.
Limitations
A main limitation is that we were only able to analyse 
individuals diagnosed with HCV infection between 
2008 and 2016, with the maximum follow-up time 
being 8.5 years, but HCV-associated disease, particu-
larly ESLD, can take 20-30 years to develop following 
acquisition of infection [14]. Whilst there is limited lit-
erature on time from acquisition of HCV infection to 
HCV diagnosis, it is thought to be at least 10 years in 
PWID [15]. Our mortality rates, therefore, may not be 
representative of all individuals with HCV infection in 
England and maybe skewed towards those with more 
advanced HCV-related disease presenting with com-
plications and these individuals may be more likely 
to be tested for HCV as a result. We do not have dis-
ease stage data to adjust for this potential bias, but 
linkage of routine laboratory reports of HCV infection 
to liver transplant registries showed a similar short 
duration to transplant registration. This bias may be 
reduced in our study through a variety of different 
means. First, it was not possible to include HCV RNA 
testing information with 25% of anti-HCV positive indi-
viduals having no HCV RNA test recorded in SSBBV; 
we would expect mortality rates in individuals with 
treated or cleared HCV infection to be lower than indi-
viduals currently infected. Second, SSBBV is derived 
from a network of laboratories that cover 40% of the 
England GP-registered population. It is possible that 
we may not have identified a person’s initial HCV test 
if they had tested outside the sentinel sites or before 
SSBBV. However, our cohort was also linked to routine 
laboratory reports of new diagnoses (established in 
1996) and HES inpatient data (established in 2004) so 
any earlier diagnosis i.e. before SSBBV started, should 
have been identified. In addition, while coverage var-
ies by region, the network is broadly representative 
for England and our analysis allowed inclusion of more 
people e.g. those testing positive but not necessarily 
referred or engaged in care, improving representative-
ness of our data. Third, there can be delays in death 
registrations, due to coroners’ inquests into cause of 
death being required. Around 5% of all deaths are not 
registered in the year they occurred, rising to 50% for 
deaths relating to drug poisonings. Our mortality rate 
estimates for external causes in more recent years 
might be an underestimate, therefore, but it is unlikely 
to impact liver disease [16].
Other evidence and implications
Our all-cause ASMRs were similar to those found in a 
study by Aspinall et al. based in Scotland [17]. There 
were some methodological differences (they calculated 
ASMRs for all individuals aged 1 years and over) and 
our mortality rates for liver cancer and alcohol associ-
ated liver disease were higher; this may be due to our 
larger sample size and only including individuals aged 
15 years and over. We also found differences in ASMRs 
between males and females. This is likely to be asso-
ciated with differences in co-morbidities e.g. smoking, 
alcohol and drug use [18,19], higher rates of spontane-
ous clearance of HCV and slower disease progression 
in females [20,21], which we were unable to adjust for. 
Alcohol misuse in HCV infected individuals can accel-
erate liver disease progression, which may explain the 
15 times higher mortality rates from alcoholic liver dis-
ease [14,22].
Table 2
Characteristics of individuals diagnosed with HCV 
infection in SSBBV, England, 2008–2016 (n = 43,895)
Characteristics 
 
 
Total Deaths
n % n %
43,895 100 2,656 6.1
Sex
Male 29,671 67.6 1,914 6.5
Female 14,224 32.4 742 5.2
Age
15–29 8,007 18.2 143 1.8
30–39 14,415 32.8 494 3.4
40–49 12,225 27.9 733 6.0
50–69 8,228 18.7 948 11.5
70 + 1,020 2.3 338 33.1
Ethnicity
White 28,599 65.2 2,311 8.1
Asian 3,984 9.1 200 5.0
Black 828 1.9 77 9.3
Other 1,249 2.8 44 3.5
Unknown 9,235 21.0 24 0.3
Diagnosis year
2008–10 16,122 36.7 1,554 9.6
2011–13 15,545 35.4 874 5.6
2014–16 12,228 27.9 228 1.9
HCV: hepatitis C virus; SSBBV: Sentinel Surveillance of Blood 
Borne Virus Testing.
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Table 3
All-cause, sex-specific and disease-specific ASMR, per 100,000 person years, for individuals diagnosed with HCV infection, 
England, 2008–2016
Characteristics
England Diagnosed with HCV infection Mortality rate ratio
ASMR 95% CI PY Deaths
Crude 
mortality 
rate
ASMR 95% CI Mortality ratio 95% CI
Age ≥ 15 years
Total 1,218.5 1,214.9–1,222.1 183,821 2,656 1,444.9 2,834.2 2,664.2–3,004.2 2.3 2.2–2.5
Sex
Male 1,391.1 1,385.2–1,397.0 123,022 1,914 1,555.8 3,170.7 2,927.2–3,414.1 2.3 2.1–2.5
Female 1,045.9 1,041.7–1,050.1 60,799 742 1,220.4 2,497.7 2,260.4–2,735.0 2.4 2.2–2.6
Cause of death
Liver Cancer 10 9.6–10.3 183,821 233 126.8 344.4 283.8–405.1 34.5 28.5–40.6
ESLD 3.4 3.3–3.6 183,821 63 34.3 27.5 18.3–36.8 8.0 5.3–10.7
Viral hepatitis 0.5 0.5–0.6 183,821 207 112.6 220.5 175.8–265.3 421.9 336.3–507.6
Non-alcoholic liver 
disease 6.5 6.2–6.7 183,821 100 54.4 76.6 54.0–99.2 11.8 8.3–15.3
Alcoholic liver disease 7.4 7.1–7.7 183,821 238 129.5 122.0 100.4–143.6 16.5 13.6–19.4
All-liver disease 
(underlying) 27.8 27.3–28.3 183,821 841 457.5 791.1 709.0–873.2 28.4 25.5–31.4
All-liver disease 
(underlying and 
contributory)a
28.5 27.9–29.0 183,821 1213 659.9 1145.1 1,044.9–1,245.2 40.2 36.7–43.7
External causes 35.8 35.2–36.4 183,821 536 291.6 221.2 193.4–248.9 6.2 5.4–6.9
Other 1,154.8 1,151.3–1,158.4 183,821 1279 695.8 1821.9 1,675.7–1,968.1 1.6 1.5–1.7
Age 30–69 years
Total 377.9 375.5–380.2 161,622 2165 1,339.5 1,768.9 1,672.3–1,865.5 4.7 4.4–4.9
Sex
Male 454.8 451.1–458.5 111,618 1,639 1,468.4 2,016.5 1,978.4–2,234.7 4.4 4.3–4.9
Female 300.9 298.0–303.9 50,005 517 1,033.9 1,431.3 1,286.7–1,575.8 4.8 4.3–5.2
Cause of death
Liver Cancer 5.2 5.0–5.5 161,622 175 108.3 206.8 169.8–243.7 39.5 32.4–46.5
ESLD 4.2 4.0–4.5 161,622 60 37.1 37.7 26.4–49.1 8.9 6.2–11.6
Viral hepatitis 0.6 0.5–0.7 161,622 173 107.0 165.2 134.0–196.4 263.6 213.8–313.4
Non-alcoholic liver 
disease 5.1 4.9–5.4 161,622 91 56.3 76.4 56.5–96.3 14.8 11.0–18.7
Alcoholic liver disease 10.1 9.7–10.5 161,622 232 143.5 169.4 142.8–196.0 16.8 14.1–19.4
All liver-disease 
(underlying) 25.4 24.8–26.0 161,622 731 452.3 655.5 595.8–715.3 25.8 23.5–28.2
All liver-disease 
(underlying and 
contributory)a
36.4 35.7–37.1 161,622 1,049 649.0 917.8 847.1–988.4 25.2 23.3–27.1
External causes 24.5 23.9–25.1 161,622 499 308.7 274.2 244.8–303.6 11.2 10.0–12.4
Other 328.1 325.9–330.2 161,622 926 572.9 839.1 769.2–909.1 2.6 2.3–2.8
ASMR: age and sex-standardised mortality rates; CI: confidence interval; ESLD: end stage liver disease; HCV: hepatitis C virus; PY: person 
years.
a Individuals with liver cancer, ESLD, viral hepatitis, alcoholic liver disease and non-alcoholic liver disease recorded as an underlying cause, or 
any of the additional nine causes recorded.
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Analysis with Joinpoint did not show a statistically 
significant decrease in all-cause and underlying and 
contributory all-liver disease mortality following the 
introduction of HCV treatment with DAAs in 2014; how-
ever the data does suggest that mortality rates have 
started to fall. Unlinked analysis of mortality records in 
England found a 3% reduction in the number of deaths 
from HCV-related ESLD and liver cancer in 2016 and a 
further 11% fall in 2017 [23], which have been largely 
attributed to improved access to new treatments. 
However, under-reporting of HCV infection remains an 
issue in mortality records [24-26]. The impact of DAAs 
and cascade of care improvements on mortality rates, 
will likely be more pronounced over time, as treatment 
restrictions are relaxed to include patients with little 
or no liver disease – thus preventing progression to 
severe liver disease with lower SVRs and higher mor-
tality risk. A small rise in mortality rates in 2014 was 
notable, which although not significant, might have 
occurred due to patients deferring treatment with 
interferon-based regimes until they became eligible for 
treatment with DAAs.
When compared with England’s general population we 
found all-cause mortality rates were 2.3 times higher 
for all adults and 4.6 times higher for individuals 30–69 
years old with a HCV infection diagnosis. These high 
rates of premature mortality are worrying and highlight 
health inequalities as this younger group are likely to 
include a sub-group of vulnerable PWID, who tend to 
have multi-substance addictions, mental health issues 
and chaotic lifestyles. Their mortality risk, therefore, 
is not only from liver causes, but also from accidents, 
international self-harm and drug-related poisonings. 
This was evident in our findings, with an almost dou-
bling of risk of death from external causes in the 30–69 
age group compared with all adults with HCV. Simmons 
et al. [24] also found external causes to be the most 
common cause of death for individuals anti-HCV posi-
tive over the same period and drug-related mortality in 
England has been increasing over the last decade [16]. 
While DAAs have an important role to play, solutions to 
address problematic drug use (the most common mode 
of transmission for HCV in England) are also important 
to prevent onward HCV spread and to reduce prema-
ture mortality from liver and drug-associated deaths.
While clinical studies are required to prove the impact 
of DAAs on HCV-associated outcomes, they are not 
Figure 
ASMR by all-cause mortality and underlying and contributory all-liver mortality for individuals aged 15 years and over, 
England, 2010–2016
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sufficient to monitor progress towards the WHO elimi-
nation goals. Numerous European countries reported 
having surveillance of HCV and mortality in a recent 
WHO survey [27] and as HCV infection is often under-
reported of mortality records, linked analysis is required 
to understand the true burden of HCV-associated dis-
ease [24-26]. As Europe works towards the elimination 
of HCV and progress monitoring is required, this meth-
odology offers a cost-effective option for analysis in 
countries with suitable datasets.
Conclusion
Mortality rates, particularly in younger individuals, 
were higher in those with a diagnosis of HCV infec-
tion compared with the general English population, 
highlighting health inequalities. Our findings provide 
a baseline of HCV-associated mortality rates pre-DAA 
and continued monitoring is required as HCV treat-
ments are scaled up to attain HCV elimination ambi-
tions. However, the high mortality rates associated with 
common co-morbidities, such as problematic drug and 
alcohol use, highlights the importance of integrated 
health and social care strategies and commissioning 
to address the needs of this vulnerable population and 
reduce inequalities. A holistic approach to drug misuse 
is required to reduce the double jeopardy of drug and 
HCV-associated mortality experienced by individuals 
with HCV infection.
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